TW200621753A - Pyrimidinylimidazoles and methods of making and using the same - Google Patents

Pyrimidinylimidazoles and methods of making and using the same

Info

Publication number
TW200621753A
TW200621753A TW094129857A TW94129857A TW200621753A TW 200621753 A TW200621753 A TW 200621753A TW 094129857 A TW094129857 A TW 094129857A TW 94129857 A TW94129857 A TW 94129857A TW 200621753 A TW200621753 A TW 200621753A
Authority
TW
Taiwan
Prior art keywords
pyrimidinylimidazoles
making
methods
same
alk
Prior art date
Application number
TW094129857A
Other languages
English (en)
Inventor
Wen-Cherng Lee
li-hong Sun
Claudio Chuaqui
Juswinder Singh
Feng Shan
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35431931&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200621753(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of TW200621753A publication Critical patent/TW200621753A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
TW094129857A 2004-08-31 2005-08-31 Pyrimidinylimidazoles and methods of making and using the same TW200621753A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60604504P 2004-08-31 2004-08-31

Publications (1)

Publication Number Publication Date
TW200621753A true TW200621753A (en) 2006-07-01

Family

ID=35431931

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094129857A TW200621753A (en) 2004-08-31 2005-08-31 Pyrimidinylimidazoles and methods of making and using the same

Country Status (6)

Country Link
EP (1) EP1786802A1 (zh)
JP (1) JP2008511631A (zh)
AU (1) AU2005280168A1 (zh)
CA (1) CA2578630A1 (zh)
TW (1) TW200621753A (zh)
WO (1) WO2006026306A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044509A2 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
MX2009003518A (es) 2006-10-03 2009-08-25 Genzyme Corp Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
CN101743234A (zh) 2007-04-30 2010-06-16 雅培制药有限公司 二酰甘油o-酰基转移酶1型酶的抑制剂
CN101910153B (zh) * 2008-01-11 2014-01-22 诺华股份有限公司 作为激酶抑制剂的嘧啶类
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
EP2660314A4 (en) 2010-12-27 2014-09-03 Lsip Llc IPS CELLS AND METHOD FOR THEIR PRODUCTION
WO2012167261A2 (en) * 2011-06-03 2012-12-06 Yale University Compositions and methods for treating and preventing neointimal stenosis
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
MX2014004994A (es) 2011-10-26 2014-08-27 Seattle Children S Res Inst Cisteamina en el tratamiento de enfermedad fibrotica.
KR102334260B1 (ko) 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Ｊａｋ2 및 ａｌｋ2 억제제 및 이들의 사용 방법
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2015135138A1 (en) * 2014-03-11 2015-09-17 Yi-Wen Wang Pharmaceutical composition and method for reducing scar formation
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
US11541149B2 (en) 2015-12-11 2023-01-03 Research Institute At Nationwide Children's Hospital Systems and methods for optimized patient specific tissue engineering vascular grafts
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
CA2498047C (en) * 2002-09-18 2009-05-19 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors

Also Published As

Publication number Publication date
AU2005280168A1 (en) 2006-03-09
EP1786802A1 (en) 2007-05-23
WO2006026306A1 (en) 2006-03-09
JP2008511631A (ja) 2008-04-17
CA2578630A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
RS20050199A (en) Imidazolopyridines and methods of making and using the same
TW200621752A (en) Pyrimidinylpyrazoles and methods of making and using the same
UA81624C2 (ru) Тризамещённые гетероарилы и способ их получения и применение
RS20050616A (en) Pyrazoles and methods of making and using the same
MXPA05002443A (es) Pirazolopiridinas y metodos para elaboracion y uso de las mismas.
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2004013120A8 (en) Novel benzodioxoles
HK1083838A1 (en) A2a adenosine receptor antagonists
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
GB0325956D0 (en) Novel compounds
WO2003093269A3 (de) Substituierte pyrazolo-pyrimidin-4-one
MY153719A (en) Prokineticin 1 receptor antagonists
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
TW200716566A (en) Prokineticin 2 receptor antagonists
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
WO2004014322A3 (en) Immunomodulatory compositions, methods of making, and methods of use thereof
GB0510143D0 (en) Novel compounds A1
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
HK1068136A1 (en) Muscarinic antagonists
MY142804A (en) Nk1 antagonists
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
GB0322510D0 (en) Novel compounds